Are orphan drugs losing their sparkle?
For more than a decade, orphan drugs’ growth has outpaced that of non-orphan prescription drugs. But the growth gap is narrowing…
How can CDMOs succeed in 2024 and beyond?
Watch our webinar to explore key growth drivers and top opportunities for CDMOs in 2024 and beyond.
Real World Data
Real-world data (RWD) is a game changer when it comes to understanding how healthcare operates in reality. Medical and pharmacy claims, lab tests and results, electronic health records, and clinical pathways combine to provide an incredibly granular glimpse into the patient journey.
Evaluate Announces Acquisition of J+D Forecasting
The combination of Evaluate’s world-class consensus forecasting and consulting expertise with J+D Forecasting’s highly specialised models, will help customers create more intelligent and consistent insights.
Competitive Intelligence
Strategic competitive intelligence in the pharma industry is a crucial but time consuming and complex task. Find out how Evaluate can provide a technology-enabled extension of your team to ensure your people are free to focus on the areas that will achieve your goals.
Evaluating Neurology
Evaluating the Cell and Gene Therapy Landscape
ADC
Evaluate radically transforms your confidence in strategic portfolio decisions.
In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines.
Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth.
HOW WE HELP
Connected data gives you a clearer picture.
Evaluate gives you the understanding and time you need to drive better decisions.
Market Opportunity Sizing
Identify the market that offers the greatest potential for your business so you can confidently prioritise assets and allocate resources.
Commercial Opportunity Assessment
Develop a robust view of potential partners and licensing opportunities to boost your pipeline and amplify your commercial success.
Competitive Landscape Analysis
Build a clear analysis of the evolving landscape – market dynamics, emerging trends and key players – and make strategic moves that strengthen your position.
Company Profiling
Monitor key companies so you can track potential partners and competitors and find opportunities in a constantly changing environment.
Asset Screening
Obtain a clear and unbiased assessment of asset value to drive licensing decisions and ensure you invest in assets with the highest potential for success.
Deal Benchmarking
Bring confidence to your allocation strategy with timely external benchmarking data across the R&D landscape.
We collect,
collaborate and connect.
OUR SOLUTIONS
Insight at Your Fingertips
Access our world-class forecasting, analysis and machine learning-driven insight to help you reduce risk, maximise returns, and make smarter decisions about your portfolio strategy.
MARKET REPORTS
Trends & Analysis
Dive into our market reports covering sector performance and valuation, emerging trends and global forecasts. Stay ahead of the competition with the latest developments that impact your portfolio strategy.
OUR SERVICES
Consulting & Analytics
Tap into our expertise and reach your goals with our collaborative team of specialists, providing technology-enabled consulting, strategic commercial insights, and recommendations across the product lifecycle.
Latest Solutions & Insights
Understand the context. Data-driven insights and analysis for the pharma, biotech and medtech sectors.
- April 24, 2024
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the ...
- April 9, 2024
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an ...
- April 4, 2024
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need ...
- March 28, 2024
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay ...
- March 27, 2024
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market ...
2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can ...